Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
57.891,33
-4,47%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Marker Therapeutics Inc (MRKR) Marker Therapeutics Inc (MRKR) Notizie

Marker Therapeutics Inc

MRKR
4,11
0,06 (1,48%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 22:00:05
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/4/202413:00GLOBEPrincipal Investigator from City of Hope National Medical..
25/3/202422:45GLOBEMarker Therapeutics Reports Year-End 2023 Corporate and..
22/3/202417:30GLOBEMarker Therapeutics to Present at the H.C. Wainwright 2nd..
01/3/202414:02EDGAR2Form 8-K - Current report
26/2/202413:58EDGAR2Form 8-K - Current report
22/1/202413:30GLOBEMarker Therapeutics Receives Approval from United States..
08/1/202414:30EDGAR2Form 8-K - Current report
08/1/202414:24GLOBEMarker Therapeutics Announces Clinical Program Updates and..
21/12/202317:00GLOBEMarker Therapeutics Announces Participation in Biotech..
11/12/202313:35EDGAR2Form 8-K - Current report
11/12/202313:00GLOBEMarker Therapeutics Announces Sustained Complete Response in..
20/11/202322:37EDGAR2Form 8-K - Current report
09/11/202323:03EDGAR2Form 8-K - Current report
09/11/202323:00GLOBEMarker Therapeutics Reports Third Quarter 2023 Financial..
09/11/202322:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/9/202313:10EDGAR2Form 8-K - Current report
11/9/202313:00GLOBEMarker Therapeutics Announces Complete Response in First..
30/8/202314:00GLOBEMarker Therapeutics to Present at the H.C. Wainwright 25th..
14/8/202322:37EDGAR2Form 8-K - Current report
14/8/202322:30GLOBEMarker Therapeutics Reports Second Quarter 2023 Financial..
14/8/202322:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202313:22EDGAR2Form 8-K - Current report
07/8/202313:00GLOBEMarker Therapeutics Reports Non-Clinical Proof-of-Concept..
26/7/202313:00GLOBEMarker Therapeutics to Participate in Virtual Roundtable..
10/7/202313:09EDGAR2Form 8-K - Current report
10/7/202313:00GLOBEEuropean Medicines Agency Grants Orphan Drug Designation for..
05/7/202322:22EDGAR2Form 3 - Initial statement of beneficial ownership of..
03/7/202322:05EDGAR2Form 8-K - Current report
30/6/202322:05EDGAR2Form 8-K - Current report
26/6/202313:00GLOBEMarker Therapeutics Reports MT-401 Non-Clinical Data in AML..
12/6/202313:00GLOBEMarker Therapeutics Announces First Lymphoma Patient Treated..
31/5/202312:30GLOBEMarker Therapeutics Reports Pre-Clinical Data of its MT-601..
08/5/202313:30GLOBEMarker Therapeutics Appoints Monic Stuart, M.D., as Chief..
Apertura: 4,05 Min: 4,05 Max: 4,27
Chiusura: 4,05

La tua Cronologia

NASDAQ
MRKR
Marker Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network